Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India
| Autor: | Hema Paul, Joy John Mammen, Malathi Murugesan, Prasad Mathews, Priscilla Rupali, Rajiv Karthik |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
History
medicine.medical_specialty COVID-19 Vaccines Polymers and Plastics Coronavirus disease 2019 (COVID-19) Health Personnel education Severe disease Disease Industrial and Manufacturing Engineering Internal medicine Health care medicine Humans Business and International Management Multidisciplinary SARS-CoV-2 business.industry Vaccination COVID-19 Healthcare worker Vaccine efficacy Reinfection Cohort business |
| Zdroj: | SSRN Electronic Journal. |
| ISSN: | 1556-5068 |
| Popis: | Background: The emergence of newer variants with the immune escape potential raises concerns about breakthroughs and re-infections resulting in future waves of infection. We examined the infection rates among a cohort of healthcare workers (HCW) in South India during the second wave driven mainly by the delta variant and examined the protective effect of prior COVID-19 disease and vaccination. Methods: Symptomatic HCWs were routinely tested by RT-PCR per institutional policy. Vaccination was offered to all HCWs between January and June 2021, and the details were documented. We set up a non-concurrent cohort to estimate infection rates and estimated efficacy of prior infection and vaccination between 16th Apr to 30th May, 2021, using a cox-proportional hazards model with time-varying covariates adjusting for daily incidence. Findings: Between June 2020 and May 2021, 2735 (23.9%) of 11,405 HCWs were infected, with 1412, including 32 re-infections, reported during the second wave. 6863 HCWs received two doses of vaccine and 1905 one dose. The protective efficacy of prior infection against symptomatic infection was 86.0% (95%CI 76.7% - 91.6%). Vaccination combined with prior infection provided 91.1% (95%CI 84.1% - 94.9%) efficacy. In the absence of prior infection, vaccine efficacy against symptomatic infection during the second wave was 31.8% (95%CI 23.5% – 39.1%). Interpretation: Prior infection provided substantial protection against symptomatic re-infection and severe disease during a delta variant driven second wave. Deferring vaccination for previously symptomatically infected individuals is a pragmatic strategy to overcome vaccine supply constraints. However, the duration of protection requires further evaluation. Funding None to declare. Declaration of Interest: None to declare. Ethical Approval: This study was approved by the institutional ethics committee and research board (IRB Min no. 13980). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|